The Weekly Wire
A weekly behavioral-health intelligence briefing: what moved, why it matters, and what to watch next.
Tracker
Tracked equities across mental health: pharma psychiatry, psychedelics, cannabis, digital health.
Delayed quotes. Last updated 12 Oct 2026, 22:22 UTC.
Clinical-stage developers of psilocybin, MDMA, and next-generation psychedelic compounds.
| Ticker | Company | Last | Change | % | |
|---|---|---|---|---|---|
| Compass Pathways | 11.53 | −0.47 | −3.92% | ||
| CMPS Compass Pathways Nasdaq · USD Psychedelics $11.53 −3.92% Oct 12, 2026, 4:00 PM ET · delayed Open $12.02 Day high $12.05 Day low $11.53 Volume 1.95M Mkt cap $1.60B 52w range $4.88–$15.87 Price · last 1M Loading chart… PipelineCOMP360 psilocybin Treatment-resistant depression FDA Ph. 3 Status Phase 3 complete; rolling NDA underway Latest milestone · Aug 5, 2026 Rolling NDA submission and initial review underway; final submission expected to be completed in Q4 (Compass Pathways Q2 2026 results press release (Form 8-K, Exhibit 99.1)) Recent coveragePsychedelic drug developers are borrowing their launch infrastructure. Few of the terms are public.Low-dose psilocybin moved autistic and non-autistic brain networks in opposite directions. Late-stage psilocybin trial records are silent on autism.The psychedelic approval debate is moving from whether the drugs work to who must deliver themProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Definium Therapeutics (formerly MindMed) | 35.20 | −1.70 | −4.61% | ||
| DFTX Definium Therapeutics (formerly MindMed) Nasdaq · USD Psychedelics $35.20 −4.61% Oct 12, 2026, 4:00 PM ET · delayed Open $36.25 Day high $36.30 Day low $34.95 Volume 1.91M Mkt cap $4.73B 52w range $10.46–$49.70 Price · last 1M Loading chart… PipelineDT120 (lysergide ODT) Major depressive disorder FDA Ph. 3 Status Phase 3 positive; second trial enrolling; FDA Breakthrough Therapy designation granted Sep 8, 2026 Latest milestone · Sep 8, 2026 FDA Breakthrough Therapy designation granted for DT120 ODT in major depressive disorder (Definium Therapeutics press release (Form 8-K, Exhibit 99.1)) DT120 (lysergide ODT) Generalized anxiety disorder FDA Ph. 3 Status Both Phase 3s positive (Voyage, Panorama); NDA filing targeted H1 2027 Latest milestone · Sep 14, 2026 Positive Phase 3 Panorama topline; pre-NDA meeting scheduled for 4Q 2026; NDA filing anticipated in 1H 2027 (Definium Therapeutics press release (Form 8-K, Exhibit 99.1)) Recent coverageDefinium Has De-Risked the Clinical Story. Its Commercial Questions Are Just Beginning.Definium's third positive DT120 trial confirms the efficacy signal. It doesn't confirm the effect size held.Definium's LSD candidate got its second Breakthrough Therapy designationProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Helus Pharma (formerly Cybin) | 11.03 | −0.77 | −6.53% | ||
| HELP Helus Pharma (formerly Cybin) Nasdaq · USD Psychedelics $11.03 −6.53% Oct 12, 2026, 4:00 PM ET · delayed Open $11.90 Day high $12.71 Day low $10.99 Volume 2.34M Mkt cap $805.9M 52w range $3.76–$15.15 Price · last 1M Loading chart… PipelineHLP003 (deuterated psilocin) Major depressive disorder FDA Ph. 3 Status Breakthrough designation; Phase 3 APPROACH enrollment completed July 2026, topline expected Q4 2026 Latest milestone · Jul 21, 2026 Enrollment completed in the Phase 3 APPROACH study (223 participants); topline data readout targeted for Q4 2026 (Helus Pharma press release (Form 6-K, Exhibit 99.1)) HLP004 (deuterated DMT) Generalized anxiety disorder FDA Ph. 2 Status Phase 2 signal-detection topline reported March 2026 (adjunct to standard of care) Latest milestone · Mar 5, 2026 Topline results announced from the Phase 2 HLP004-002 study in generalized anxiety disorder (Helus Pharma MD&A for the quarter ended 2026-06-30 (Form 6-K, Exhibit 99.2)) Recent coveragePsychedelic drug developers are borrowing their launch infrastructure. Few of the terms are public.Psilocybin's strongest results are in anxiety. Almost nobody is developing it for anxiety.Helus Pharma's pipeline is built around the two practical objections to psychedelic psychiatry, not the scientific onesProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| GH Research | 20.02 | −1.09 | −5.16% | ||
| GHRS GH Research Nasdaq · USD Psychedelics $20.02 −5.16% Oct 12, 2026, 4:00 PM ET · delayed Open $21.06 Day high $21.23 Day low $20.01 Volume 229.7K Mkt cap $1.37B 52w range $12.04–$31.44 Price · last 1M Loading chart… PipelineGH001 (inhaled mebufotenin) Treatment-resistant depression FDA Ph. 2 Status Phase 2b positive; FDA written responses confirm CMC and device plans appear Phase 3 ready; pivotal program initiation targeted in 2026 Latest milestone · Aug 6, 2026 FDA written responses (received July 2026) confirmed CMC and device plans appear Phase 3 ready; initiation of the pivotal program targeted in 2026 (GH Research second-quarter 2026 results press release (Form 6-K, Exhibit 99.3)) Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
Established and emerging makers of antidepressants, antipsychotics, and novel-mechanism CNS drugs.
| Ticker | Company | Last | Change | % | |
|---|---|---|---|---|---|
| Supernus Pharmaceuticals | 42.81 | +0.14 | +0.33% | ||
| SUPN Supernus Pharmaceuticals Nasdaq · USD Pharma $42.81 +0.33% Oct 12, 2026, 4:00 PM ET · delayed Open $42.67 Day high $43.18 Day low $41.90 Volume 914.6K Mkt cap $2.49B 52w range $40.51–$59.68 Price · last 1M Loading chart… Tracked mental-health programsZuranolone (Zurzuvae) Postpartum depression FDA Approved Status Marketed for PPD; not approved for MDD in the U.S. Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Axsome Therapeutics | 166.00 | −2.35 | −1.40% | ||
| AXSM Axsome Therapeutics Nasdaq · USD Pharma $166.00 −1.40% Oct 12, 2026, 4:00 PM ET · delayed Open $169.41 Day high $170.80 Day low $165.02 Volume 663.0K Mkt cap $8.70B 52w range $119.20–$260.19 Price · last 1M Loading chart… Tracked mental-health programsAXS-05 (Auvelity) Major depressive disorder FDA Approved Status Marketed AXS-05 (Auvelity) Agitation associated with dementia due to Alzheimer's disease FDA Approved Status FDA approved April 2026 Latest milestone · Apr 30, 2026 FDA approved AUVELITY for the treatment of agitation associated with dementia due to Alzheimer's disease (Axsome Therapeutics press release (Form 8-K, Exhibit 99.1)) Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Neurocrine Biosciences | 141.37 | −1.07 | −0.75% | ||
| NBIX Neurocrine Biosciences Nasdaq · USD Pharma $141.37 −0.75% Oct 12, 2026, 4:00 PM ET · delayed Open $142.37 Day high $143.63 Day low $140.93 Volume 1.08M Mkt cap $14.37B 52w range $122.14–$186.12 Price · last 1M Loading chart… Tracked mental-health programsNBI-1117568 (M4 agonist) Schizophrenia Ph. 3 Status Phase 3 program recruiting (three registration studies plus relapse-prevention); Phase 2 in bipolar I mania Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Acadia Pharmaceuticals | 19.41 | −0.37 | −1.87% | ||
| ACAD Acadia Pharmaceuticals Nasdaq · USD Pharma $19.41 −1.87% Oct 12, 2026, 4:00 PM ET · delayed Open $19.70 Day high $19.87 Day low $19.40 Volume 1.18M Mkt cap $3.34B 52w range $19.32–$30.96 Price · last 1M Loading chart… Tracked mental-health programsRemlifanserin (formerly ACP-204) Alzheimer's disease psychosis FDA Ph. 3 Status Phase 2 portion of RADIANT narrowly missed its primary endpoint (p=0.0603); company plans to continue its two ongoing Phase 3 studies in ADP, without the 30 mg arm; FDA Fast Track granted July 2026; Phase 2 in Lewy body dementia psychosis ongoing Latest milestone · Sep 24, 2026 Phase 2 RADIANT topline: primary endpoint narrowly missed (SAPS-H+D p=0.0603); company plans to continue enrolling its two ongoing Phase 3 studies and remove the 30 mg arm (Acadia Pharmaceuticals press release (Form 8-K, Exhibit 99.1)) Recent coverageNIMH is testing whether ketamine's benefit can be separated from its baggage. The answer is not obvious.Ketamine is being pushed into every hard psychiatric indication at once. Here is what is driving it.The rapid-acting antidepressant race is being won on the clock, not the receptor.Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Eli Lilly | 1182.62 | +3.35 | +0.28% | ||
| LLY Eli Lilly NYSE · USD Pharma $1182.62 +0.28% Oct 12, 2026, 4:00 PM ET · delayed Open $1181.24 Day high $1188.58 Day low $1172.81 Volume 1.25M Mkt cap $1.05T 52w range $783.85–$1292.65 Price · last 1M Loading chart… Tracked mental-health programsBrenipatide (LY3537031) Major depressive disorder; alcohol use disorder Ph. 3 Status Phase 3 recruiting in MDD and alcohol use disorder; Phase 2 in bipolar disorder and schizophrenia BPL-003 (intranasal mebufotenin) Treatment-resistant depression FDA Ph. 3 Status Phase 3 initiated; Lilly acquisition closed Sept 11, 2026 Latest milestone · Sep 11, 2026 Lilly completed its acquisition of AtaiBeckley, whose lead program BPL-003 (FDA Breakthrough Therapy designation) has initiated Phase 3 activities (AtaiBeckley Form 8-K (Items 2.01, 3.01, 3.03, 5.01, 5.02, 5.03 and 9.01)) VLS-01 (buccal DMT) Treatment-resistant depression Ph. 2 Status Phase 2b Elumina study in TRD: last patient dosed; topline results anticipated Q4 2026 Latest milestone · Aug 11, 2026 Phase 2b Elumina study in TRD: last patient dosed; topline results anticipated in Q4 2026 (AtaiBeckley Form 10-Q for the quarter ended 2026-06-30) Recent coverageLilly's AtaiBeckley deal has closed. $2.8 billion was fixed; another $1 billion remains contingent.One Lilly compound is now in six neuropsychiatric indications at once, Phase 3 in twoFour companies are leading psychedelics into pharma, and they're running four different strategies, not one raceProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Johnson & Johnson | 263.73 | +2.29 | +0.88% | ||
| JNJ Johnson & Johnson NYSE · USD Pharma $263.73 +0.88% Oct 12, 2026, 4:00 PM ET · delayed Open $261.60 Day high $264.39 Day low $260.37 Volume 5.64M Mkt cap $635.56B 52w range $184.66–$281.07 Price · last 1M Loading chart… Tracked mental-health programsEsketamine (Spravato) Treatment-resistant depression FDA Approved Status FDA approved as monotherapy for adults with treatment-resistant depression (January 2025) Latest milestone · Jan 21, 2025 FDA approved SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression (Johnson & Johnson press release, January 21, 2025) Seltorexant Major depressive disorder with insomnia symptoms Ph. 3 Status MDD3001 positive; MDD3005 vs quetiapine XR missed primary endpoint (Sept 2025); additional Phase 3 recruiting Latest milestone · Sep 22, 2025 Phase 3 MDD3005 against quetiapine XR: numerically greater 26-week response (57.4% vs 53.4%), primary endpoint not met (Johnson & Johnson press release, September 22, 2025) Recent coveragePsychedelic drug developers are borrowing their launch infrastructure. Few of the terms are public.Almost every branded psychiatric drug in America now sits inside a pricing deal nobody voted onSeltorexant needed to beat quetiapine head-to-head. It didn't.Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| AbbVie | 281.12 | +4.65 | +1.68% | ||
| ABBV AbbVie NYSE · USD Pharma $281.12 +1.68% Oct 12, 2026, 4:03 PM ET · delayed Open $277.65 Day high $281.27 Day low $276.01 Volume 5.49M Mkt cap $496.77B 52w range $190.75–$281.27 Price · last 1M Loading chart… Tracked mental-health programsEmraclidine Schizophrenia Ph. 2 Status Phase 2 EMPOWER trials missed their primary endpoint; AbbVie recorded a $4.5B impairment. A separate Phase 2 schizophrenia study remains ongoing. Recent coverageFour companies are leading psychedelics into pharma, and they're running four different strategies, not one raceMedicare price negotiation already reached psychiatric drugs. A proposed rule would make it permanent.Cobenfy works. The muscarinic class keeps failing everywhere else.Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
Multi-state operators, cannabinoid-pharma names, and the ETFs that track the sector.
| Ticker | Company | Last | Change | % | |
|---|---|---|---|---|---|
| Curaleaf | 9.25 | −0.14 | −1.49% | ||
| CURLF Curaleaf OTCQX · USD Cannabis $9.25 −1.49% Oct 12, 2026, 3:59 PM ET · delayed Open $9.26 Day high $9.30 Day low $8.99 Volume 35.3K Mkt cap $2.45B 52w range $5.40–$15.15 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Green Thumb | 6.59 | −0.03 | −0.45% | ||
| GTBIF Green Thumb OTCQX · USD Cannabis $6.59 −0.45% Oct 12, 2026, 3:59 PM ET · delayed Open $6.62 Day high $6.91 Day low $6.53 Volume 110.5K Mkt cap $1.44B 52w range $5.29–$10.43 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Trulieve | 10.39 | −0.28 | −2.62% | ||
| TRLV Trulieve NYSE · USD Cannabis $10.39 −2.62% Oct 12, 2026, 4:00 PM ET · delayed Open $10.69 Day high $10.87 Day low $10.35 Volume 983.0K Mkt cap $2.00B 52w range $4.62–$13.28 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Verano | 5.01 | −0.20 | −3.84% | ||
| VRNO Verano OTCQX · USD Cannabis $5.01 −3.84% Oct 12, 2026, 3:59 PM ET · delayed Open $5.27 Day high $5.27 Day low $4.86 Volume 85.4K Mkt cap $366.8M 52w range $3.91–$9.75 Price · last 1M Loading chart… Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Tilray Brands | 3.36 | −0.18 | −5.08% | ||
| TLRY Tilray Brands Nasdaq · USD Cannabis $3.36 −5.08% Oct 12, 2026, 4:00 PM ET · delayed Open $3.55 Day high $3.56 Day low $3.34 Volume 3.88M Mkt cap $496.6M 52w range $3.34–$18.40 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Canopy Growth | 0.76 | −0.07 | −8.41% | ||
| CGC Canopy Growth Nasdaq · USD Cannabis $0.76 −8.41% Oct 12, 2026, 4:00 PM ET · delayed Open $0.83 Day high $0.84 Day low $0.74 Volume 5.31M Mkt cap $340.3M 52w range $0.74–$2.38 Price · last 1M Loading chart… Profile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| MSOS | AdvisorShares MSOS ETF | 4.20 | −0.14 | −3.23% | |
| MJ | Amplify Alternative Harvest ETF | 23.04 | −0.72 | −3.05% | |
Telehealth psychiatry, therapy platforms, and behavioral-health facility operators.
| Ticker | Company | Last | Change | % | |
|---|---|---|---|---|---|
| Teladoc Health | 5.92 | +0.15 | +2.60% | ||
| TDOC Teladoc Health NYSE · USD Digital $5.92 +2.60% Oct 12, 2026, 4:00 PM ET · delayed Open $5.82 Day high $5.98 Day low $5.73 Volume 3.25M Mkt cap $1.08B 52w range $4.40–$9.89 Price · last 1M Loading chart… Recent coveragePrescription digital therapeutics and the HCPCS codes that will define the categoryHims, Talkspace, and the coming reckoning on telehealth psychiatry marginsProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Hims & Hers | 30.64 | −0.28 | −0.91% | ||
| HIMS Hims & Hers NYSE · USD Digital $30.64 −0.91% Oct 12, 2026, 4:00 PM ET · delayed Open $30.92 Day high $31.78 Day low $30.33 Volume 8.92M Mkt cap $7.15B 52w range $13.74–$65.30 Price · last 1M Loading chart… Recent coverageDigital mental health didn't get disrupted. It got absorbed.The 2026 mental health milestones are real. The headlines about them are wrong.Hims, Talkspace, and the coming reckoning on telehealth psychiatry marginsProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| LifeMD | 2.55 | −0.08 | −3.04% | ||
| LFMD LifeMD Nasdaq · USD Digital $2.55 −3.04% Oct 12, 2026, 4:00 PM ET · delayed Open $2.65 Day high $2.65 Day low $2.53 Volume 626.4K Mkt cap $123.1M 52w range $2.53–$6.53 Price · last 1M Loading chart… Recent coverageHims, Talkspace, and the coming reckoning on telehealth psychiatry marginsProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Acadia Healthcare | 30.08 | +0.83 | +2.84% | ||
| ACHC Acadia Healthcare Nasdaq · USD Digital $30.08 +2.84% Oct 12, 2026, 4:00 PM ET · delayed Open $29.10 Day high $30.20 Day low $29.07 Volume 1.20M Mkt cap $2.80B 52w range $11.43–$35.83 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||
| Universal Health Services | 178.83 | +1.48 | +0.83% | ||
| UHS Universal Health Services NYSE · USD Digital $178.83 +0.83% Oct 12, 2026, 4:00 PM ET · delayed Open $177.56 Day high $181.20 Day low $177.24 Volume 558.3K Mkt cap $10.54B 52w range $140.08–$246.33 Price · last 1M Loading chart… Recent coverageProfile facts come from the company's SEC filings; hover a value for its source and date. Quotes are delayed. | |||||